CSL Ltd (ASX: CSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CSL Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$84.09 billion
P/E Ratio
18.99
Dividend Yield
2.60%
Shares Outstanding
485.15 million
Earnings per share
6.170
Dividend per share
4.52
Year To Date Return
0.95%
Earnings Yield
5.27%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CSL Ltd (ASX: CSL)
Latest News
Broker Notes
CSL shares: 5 analysts encouraging investors to buy the dip and why
Broker Notes
Fully-valued: Experts highlight 3 ASX 200 shares to hold but not buy afresh today
Growth Shares
3 Australian stocks for smart investors to buy and hold
Share Fallers
Which ASX shares had the biggest price drops after their results?
Share Market News
Can you guess the best and worst performing sectors during earnings season?
Share Market News
10 ASX 200 shares trading below the market average P/E ratio today
Healthcare Shares
3 reasons CSL shares could rocket 40% into 2026
Healthcare Shares
Why did CSL shares crash 21% in August?
Share Fallers
The worst 3 ASX 200 stocks to buy and hold in August unmasked
Broker Notes
Macquarie's top ASX 200 share picks in each of the 11 market sectors
How to invest
How much will I have if I invest $1,000 a month in ASX shares for 30 years?
How to invest
How to build a million-dollar ASX share portfolio in 25 years
Frequently Asked Questions
-
CSL was listed on the ASX in June 1994.
-
CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.
Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.
-
CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.
-
CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 09 Sep 2025 | $2.4508 | 0.00% | Final | 03 Oct 2025 |
| 10 Mar 2025 | $2.0711 | 0.00% | Interim | 09 Apr 2025 |
| 09 Sep 2024 | $2.1746 | 0.00% | Final | 02 Oct 2024 |
| 11 Mar 2024 | $1.7989 | 0.00% | Interim | 03 Apr 2024 |
| 11 Sep 2023 | $2.0078 | 6.42% | Final | 04 Oct 2023 |
| 09 Mar 2023 | $1.6215 | 0.00% | Interim | 05 Apr 2023 |
| 06 Sep 2022 | $1.7583 | 10.00% | Final | 05 Oct 2022 |
| 07 Mar 2022 | $1.4229 | 0.00% | Interim | 06 Apr 2022 |
| 02 Sep 2021 | $1.5897 | 10.00% | Final | 30 Sep 2021 |
| 04 Mar 2021 | $1.3491 | 0.00% | Interim | 01 Apr 2021 |
| 10 Sep 2020 | $1.4696 | 0.00% | Final | 09 Oct 2020 |
| 11 Mar 2020 | $1.4713 | 0.00% | Interim | 09 Apr 2020 |
| 10 Sep 2019 | $1.4545 | 0.00% | Final | 11 Oct 2019 |
| 13 Mar 2019 | $1.2032 | 0.00% | Interim | 12 Apr 2019 |
| 11 Sep 2018 | $1.2782 | 0.00% | Final | 12 Oct 2018 |
| 14 Mar 2018 | $1.0050 | 0.00% | Interim | 13 Apr 2018 |
| 12 Sep 2017 | $0.0000 | 0.00% | Final | 13 Oct 2017 |
| 15 Mar 2017 | $0.8378 | 0.00% | Interim | 13 Apr 2017 |
| 13 Sep 2016 | $0.8867 | 0.00% | Final | 07 Oct 2016 |
| 23 Mar 2016 | $0.8147 | 0.00% | Interim | 15 Apr 2016 |
| 07 Sep 2015 | $0.8999 | 0.00% | Final | 02 Oct 2015 |
| 16 Mar 2015 | $0.7439 | 0.00% | Interim | 10 Apr 2015 |
| 08 Sep 2014 | $0.6485 | 0.00% | Final | 03 Oct 2014 |
| 05 Mar 2014 | $0.5888 | 0.00% | Interim | 04 Apr 2014 |
| 09 Sep 2013 | $0.5698 | 0.00% | Final | 04 Oct 2013 |
| 05 Mar 2013 | $0.3406 | 0.00% | Interim | 05 Apr 2013 |
| 17 Sep 2012 | $0.3290 | 0.00% | Final | 12 Oct 2012 |
| 14 Mar 2012 | $0.2520 | 0.00% | Interim | 13 Apr 2012 |
| 19 Sep 2011 | $0.3210 | 6.23% | Final | 14 Oct 2011 |
| 08 Mar 2011 | $0.2450 | 0.00% | Interim | 08 Apr 2011 |
| 13 Sep 2010 | $0.3308 | 15.96% | Final | 08 Oct 2010 |
| 09 Mar 2010 | $0.2450 | 0.00% | Interim | 09 Apr 2010 |
| 14 Sep 2009 | $0.2800 | 0.00% | Final | 09 Oct 2009 |
| 17 Sep 2007 | $0.4675 | 58.82% | Final | 12 Oct 2007 |
| 14 Mar 2006 | $0.1960 | 0.00% | Interim | 13 Apr 2006 |
| 30 Aug 2005 | $0.0753 | 23.64% | Special | 10 Oct 2005 |
| 30 Aug 2005 | $0.3000 | 100.00% | Final | 10 Oct 2005 |
| 29 Mar 2004 | $0.1200 | 100.00% | Interim | 13 Apr 2004 |
CSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CSL Ltd
CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.
CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.
CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).
The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.
CSL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $173.32 | $-1.78 | -1.02% | 682,808 | $175.01 | $175.86 | $173.32 |
| 12 Jan 2026 | $175.10 | $0.81 | 0.46% | 573,969 | $174.50 | $175.62 | $174.00 |
| 09 Jan 2026 | $174.29 | $-0.16 | -0.09% | 740,858 | $175.00 | $175.60 | $173.47 |
| 08 Jan 2026 | $174.45 | $4.45 | 2.62% | 944,446 | $175.10 | $175.10 | $172.00 |
| 07 Jan 2026 | $170.00 | $1.71 | 1.02% | 1,039,843 | $168.80 | $170.52 | $168.65 |
| 06 Jan 2026 | $168.29 | $-4.17 | -2.42% | 1,051,387 | $172.50 | $173.30 | $168.29 |
| 05 Jan 2026 | $172.46 | $0.50 | 0.29% | 484,026 | $172.01 | $173.02 | $171.75 |
| 02 Jan 2026 | $171.96 | $-0.69 | -0.40% | 459,420 | $173.50 | $173.87 | $171.90 |
| 31 Dec 2025 | $172.65 | $0.23 | 0.13% | 474,918 | $172.50 | $173.46 | $172.00 |
| 30 Dec 2025 | $172.42 | $-1.13 | -0.65% | 507,640 | $173.70 | $174.05 | $172.04 |
| 29 Dec 2025 | $173.55 | $2.07 | 1.21% | 818,551 | $172.50 | $174.23 | $171.75 |
| 24 Dec 2025 | $171.48 | $-4.18 | -2.38% | 542,529 | $175.60 | $175.82 | $171.48 |
| 23 Dec 2025 | $175.66 | $-0.65 | -0.37% | 683,948 | $176.90 | $177.47 | $175.59 |
| 22 Dec 2025 | $176.31 | $1.23 | 0.70% | 554,540 | $178.20 | $178.87 | $175.54 |
| 19 Dec 2025 | $175.08 | $1.09 | 0.63% | 1,930,903 | $175.00 | $176.32 | $174.72 |
| 18 Dec 2025 | $173.99 | $0.60 | 0.35% | 1,175,326 | $173.09 | $174.81 | $171.64 |
| 17 Dec 2025 | $173.39 | $-3.76 | -2.12% | 1,215,809 | $176.12 | $177.00 | $172.55 |
| 16 Dec 2025 | $177.15 | $-2.16 | -1.20% | 1,578,336 | $179.77 | $179.77 | $177.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Nov 2025 | Brian Daniels | Buy | 3,400 | $99,746 |
On-market trade. US$, 1,700 ADRs (representing 3,400 ordinary shares)
in CSL Limited. |
| 29 Oct 2025 | Paul McKenzie | Issued | 58,360 | $9,966,137 |
As advised by the company. 140,520 Performance Share Units
|
| 01 Sep 2025 | Paul McKenzie | Issued | 8,101 | $1,703,397 |
Conversion of securities.
|
| 01 Sep 2025 | Paul McKenzie | Exercise | 8,101 | $1,703,397 |
Conversion of securities. 82,160 Performance Share Units
|
| 01 Sep 2025 | Paul McKenzie | Sell | 3,699 | $772,402 |
On-market trade.
|
| 01 Sep 2025 | Paul McKenzie | Expiry | 13,261 | $2,788,390 |
As advised by the company. Lapsed, 90,261 Rights
|
| 27 Aug 2025 | Samantha (Sam) Lewis | Issued | 305 | $66,907 |
Director remuneration. Weighted Average Price. 305 rights
|
| 27 Aug 2025 | Robert Cuthbertson | Issued | 366 | $80,288 |
Director remuneration. Weighted Average Price. 366 rights
|
| 27 Aug 2025 | Marie McDonald | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price. 244 rights
|
| 27 Aug 2025 | Carolyn Hewson | Issued | 488 | $107,051 |
Director remuneration. 488 Rights. Weighted Average Price
|
| 27 Aug 2025 | Alison Watkins | Issued | 427 | $93,670 |
Director remuneration. Weighted Average Price 427 rights
|
| 27 Aug 2025 | Brian McNamee | Issued | 866 | $189,972 |
Director remuneration. Weighted Average Price. 866 Rights
|
| 27 Aug 2025 | Megan Clark | Issued | 366 | $80,288 |
Director remuneration. 366 Rights. Weighted Average Price
|
| 27 Aug 2025 | Brian Daniels | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price of $219.368283
364 rights |
| 27 Aug 2025 | Elaine Sorg | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price. 416 Rights
|
| 22 Aug 2025 | Robert Cuthbertson | Exercise | 132 | $28,591 |
Conversion of securities.
|
| 22 Aug 2025 | Robert Cuthbertson | Buy | 132 | $28,591 |
Conversion of securities.
|
| 22 Aug 2025 | Brian McNamee | Exercise | 312 | $67,579 |
Conversion of securities.
|
| 22 Aug 2025 | Brian McNamee | Buy | 312 | $67,579 |
Conversion of securities.
|
| 22 Aug 2025 | Alison Watkins | Exercise | 154 | $33,356 |
Conversion of securities.
|
| 22 Aug 2025 | Alison Watkins | Buy | 154 | $33,356 |
Conversion of securities.
|
| 22 Aug 2025 | Carolyn Hewson | Buy | 176 | $38,121 |
Conversion of securities.
|
| 22 Aug 2025 | Carolyn Hewson | Exercise | 176 | $38,121 |
Conversion of securities.
|
| 22 Aug 2025 | Samantha (Sam) Lewis | Buy | 110 | $23,826 |
Conversion of securities.
|
| 22 Aug 2025 | Samantha (Sam) Lewis | Exercise | 110 | $23,826 |
Conversion of securities.
|
| 22 Aug 2025 | Marie McDonald | Exercise | 88 | $19,060 |
Conversion of securities.
|
| 22 Aug 2025 | Marie McDonald | Buy | 88 | $19,060 |
Conversion of securities.
|
| 22 Aug 2025 | Megan Clark | Exercise | 132 | $28,591 |
Conversion of securities.
|
| 22 Aug 2025 | Megan Clark | Buy | 132 | $28,591 |
Conversion of securities.
|
| 17 Mar 2025 | Megan Clark | Buy | 200 | $50,012 |
On-market trade.
|
| 19 Feb 2025 | Elaine Sorg | Issued | 172 | $44,261 |
Issue of securities. 172 Right
|
| 19 Feb 2025 | Brian Daniels | Issued | 120 | $30,880 |
Issue of securities. vwap, 120 rights
|
| 19 Feb 2025 | Megan Clark | Exercise | 132 | $34,960 |
Conversion of securities. 132 Rights
|
| 19 Feb 2025 | Megan Clark | Buy | 132 | $34,960 |
Conversion of securities.
|
| 19 Feb 2025 | Marie McDonald | Buy | 88 | $23,306 |
Conversion of securities.
|
| 19 Feb 2025 | Marie McDonald | Exercise | 88 | $23,306 |
Conversion of securities. 88 Rights
|
| 19 Feb 2025 | Samantha (Sam) Lewis | Exercise | 110 | $29,133 |
Conversion of securities. 110 Rights
|
| 19 Feb 2025 | Samantha (Sam) Lewis | Buy | 110 | $29,133 |
Conversion of securities.
|
| 19 Feb 2025 | Carolyn Hewson | Buy | 176 | $46,613 |
Conversion of securities.
|
| 19 Feb 2025 | Carolyn Hewson | Exercise | 176 | $46,613 |
Conversion of securities. 176 Rights
|
| 19 Feb 2025 | Alison Watkins | Exercise | 154 | $40,786 |
Cancellation of securities. 154 Rights
|
| 19 Feb 2025 | Alison Watkins | Buy | 154 | $40,786 |
Conversion of securities.
|
| 19 Feb 2025 | Brian McNamee | Buy | 313 | $82,898 |
Conversion of securities.
|
| 19 Feb 2025 | Brian McNamee | Exercise | 313 | $82,898 |
Conversion of securities. 312 Rights
|
| 19 Feb 2025 | Robert Cuthbertson | Exercise | 132 | $34,960 |
Conversion of securities. 132 Rights
|
| 19 Feb 2025 | Robert Cuthbertson | Buy | 132 | $34,960 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Carolyn Judith Hewson | Non-Executive Director | Dec 2019 |
Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has long term non executive experience in a few sectors bringing experience and insight on strategy, capital management and portfolio optimization through cycles, financial and non financial risk, social value, organizational culture and the changing external environment. She is Chair of the Corporate Governance Committee, Member of the Risk Management Committee, Member of the Human Resources Committee.
|
| Ms Alison Mary Watkins | Non-Executive Director | Aug 2021 |
Ms Watkins brings experience through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is a Member of the Reserve Bank Monetary Policy Board (since March 2025) and 2025). She is Chair of the Risk Management Committee, Member of the Human Resources Committee, Member of the Corporate Governance Committee and a Member of the Disclosure Committee.
|
| Dr Brian Anthony McNamee | Non-Executive DirectorNon-Executive Chairman | Jan 1990 |
Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued several private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is a Member of the Innovation and Development Committee, Member of the Disclosure Committee, Member of the Corporate Governance Committee.
|
| Dr Robert Andrew Cuthbertson | Non-Executive Director | Oct 2018 |
Professor Cuthbertson has over 35 years of experience in medical research and biotech development with large biopharmaceutical companies and medical organizations. He also has non executive director experience. Prior to CSL, he was a senior scientist at Genentech Inc., a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life threatening diseases. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is Chair of the Innovation and Development Committee, Member of the Corporate Governance Committee.
|
| Ms Samantha (Sam) Louise Lewis | Non-Executive Director | Jan 2024 |
Ms Lewis has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Prior to becoming a Non executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner from 2000 until 2014. In that role, she acted as lead auditor of several major Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs and debt/equity raisings. Ms Lewis has experience of working with companies in the manufacturing, retail and industrial sectors. She is currently a Non-executive Director at APA Group Limited and Australia Pacific Airports Corporation Limited.
|
| Mr Gordon Naylor | Non-Executive Director | Dec 2025 |
--
|
| Dr Paul McKenzie | Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director | Dec 2022 |
Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organizations. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol Myers Squibb and Merck. He is a Member of the Innovation and Development Committee.
|
| Ms Elaine Sorg | Non-Executive Director | Sep 2024 |
Ms Sorg has more than 35 years of experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie's US commercial operations. Ms Sorg's experience extends across biopharmaceutical industry and brands across therapeutic areas as well as segments. She is a Member of the Innovation and Development Committee.
|
| Dr Brian Daniels | Non-Executive Director | Dec 2024 |
Dr Daniels has over 30 years of experience in clinical development, medical affairs, commercialization and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018. Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across several therapeutic areas including in Cardio Vascular, Virology and Oncology. He is a Member of the Innovation and the Development Committee.
|
| Mr Cameron Bruce Price | Non-Executive Director | Oct 2025 |
Mr. Price will shortly retire as General Counsel & Chief Risk Officer at the Future Fund, Australia's
Sovereign Wealth Fund, which manages the global investment of several funds including the $240 billion Future Fund and the $24 billion Medical Research Future Fund. He held this role for 11 years. Prior to that Cameron was a senior commercial lawyer, partner and Board member at Allens specialising in mergers & acquisitions, equity capital markets and corporate governance and compliance. |
| Mr Constantine Saroukos | Non-Executive Director | Dec 2025 |
--
|
| Ms Fiona Mead | Company SecretaryHead of Group Governance | Jun 2018 |
-
|
| Kate Priestman | Chief Corporate & External Affairs Officer |
-
|
|
| Joy Linton | Chief Financial Officer |
-
|
|
| Roanne Parry | Chief Human Resources Officer |
-
|
|
| Mary Oates | Chief Operating Officer |
-
|
|
| Fiona Mead | Company SecretaryHead of Group Governance |
-
|
|
| Ken Lim | Executive Vice President and Chief Strategy Officer |
-
|
|
| Andy Schmeltz | Executive Vice President CSL Behring |
-
|
|
| Mark Hill | Executive Vice President Chief Digital Information Officer |
-
|
|
| Bill Mezzanotte | Executive Vice President Head of Research & Development and Chief Medical Officer |
-
|
|
| Greg Boss | Executive Vice President Legal and CSL Group General Counsel |
-
|
|
| Herve Gisserot | Senior Vice President and General Manager CSL Vifor |
-
|
|
| Dave Ross | Senior Vice President and General Manager CSL Seqirus |
-
|
|
| John Levy | Senior Vice President Enterprise Accelerator |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 166,361,570 | 34.36% |
| J P Morgan Nominees Australia Pty Limited | 83,504,097 | 17.25% |
| Citicorp Nominees Pty Limited | 49,704,198 | 10.26% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 11,954,183 | 2.47% |
| BNP Paribas Noms Pty Ltd | 8,982,224 | 1.86% |
| National Nominees Limited | 5,141,190 | 1.06% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 3,653,663 | 0.75% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 3,494,546 | 0.72% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,363,436 | 0.69% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,342,620 | 0.69% |
| Australian Foundation Investment Company Limited | 2,318,500 | 0.48% |
| Solium Nominees (Australia) Pty Ltd <Allocated A/C> | 1,773,344 | 0.37% |
| Custodial Services Limited <Beneficiaries Holding A/C> | 1,465,611 | 0.30% |
| Mutual Trust Pty Ltd | 1,436,680 | 0.30% |
| Argo Investments Limited | 1,351,509 | 0.28% |
| HSBC Custody Nominees (Australia) Limited i | 1,206,548 | 0.25% |
| BNP Paribas Noms (Nz) Ltd | 1,041,467 | 0.22% |
| Solium Nominees (Australia) Pty Ltd <Vsa A/C> | 1,022,296 | 0.21% |
| UBS Nominees Pty Ltd | 984,834 | 0.20% |
| D W S Nominees Pty Ltd | 793,208 | 0.16% |
